VitalHub Increases Q2 2021 Revenue to $5.8M While Continuing to Improve on Financial Metrics Across the Business
August 24 2021 - 5:34PM
VitalHub Corp. (the “Company” or “VitalHub”) (TSXV: VHI) announced
today it has filed its Interim Condensed Consolidated Financial
Statements and Management's Discussion and Analysis report for the
three and six months ended June 30, 2021 with the Canadian
securities authorities. These documents may be viewed under the
Company's profile at www.sedar.com.
When asked to comment on the results, VitalHub
CEO Dan Matlow said,
“With the constraints of COVID-19 in the
background, we are very happy with the progress of the Company over
the last 4 quarters. With the acquisition of Alamac Limited, our
Annual Recurring Revenue (“ARR”) now exceeds a run-rate of $21
million. Notably, over the last four quarters the Company has
added over $3.4 million in ARR organically. This represents a 46%
growth in organic annual recurring revenue over and above the $8.8
million annual recurring revenue purchased through acquisitions.
The Company is approaching our target of 20% Adjusted EBITDA, with
18% Adjusted EBITDA reported in Q2 2021. We continue to work on
integrating our acquired companies to generate increased synergies
both from a revenue and cost perspective.”
The Company will be holding a conference call
via Zoom on August 25, 2021, at 9:00am EST hosted by CEO Dan Matlow
and CFO Brian Goffenberg with a Q&A session to follow. To
register for the conference call please visit: VitalHub Q2
2021 Conference Call or https://bit.ly/VitalHubQ221.
Second Quarter 2021 Financial
Highlights
- Revenue of $5,792,182, an increase
of $3,043,287 or 111% from the comparative period in the prior
year.
- Gross profit as a percentage of
revenue for Q2 2021 was 77% compared to 73% in Q2 2020.
- ARR (Non-IFRS measure) grew by
$3,825,678 ($501,835 or 3.15% organic and $3,323,843 or 20.86%
acquisition) to $19,757,306, a 24% sequential growth in Q2 2021
versus Q1 2021.
- Net (loss) of ($523,400) compared
to net income of $179,467 from the comparative period in the prior
year.
- EBITDA (Non-IFRS measure) of
$157,114 compared to $705,901 from the comparative period in the
prior year.
- Adjusted EBITDA (Non-IFRS measure)
of $1,053,686, or 18% of revenue, compared to $754,262 or 27% of
revenue from the comparative period in the prior year.
- Cash on hand at June 30, 2021 was
$21,043,380 compared to $23,391,946 as at December 31, 2020
- Cash provided by operating
activities increased by $2,133,665 from $24,543 in Q2 2020 to
$2,158,208 in Q2 2021.
- Including the acquisition of Alamac
subsequent to the quarter, Vitalhub’s ARR now stands at
$21,057,306.
Second Quarter 2021 Business
Highlights
- The Company continues to increase
its international presence and cross sell products with additional
licensing deals won in Q2 2021 as follows:
- Licensing of Intouch with Health’s
digital health platform with University Hospitals Coventry and
Warwickshire NHS Trust,
- Multi-year large-scale licensing
transaction of Intouch with Health’s Synopsis product with
Hampshire Hospitals NHS Foundation Trust,
- Five-year licensing contract of
Vitalhub’s Treat product to Family Service Toronto,
- Multi-year license agreement of
Intouch with Health’s patient flow solution with Wrightington Wigan
and Leigh Teaching Hospitals NHS Foundation Trust,
- Multi-year license agreement of
Intouch with Health’s digital health platform with University
Hospitals Dorset NHS Foundation Trust to Support New NHS
Initiative,
- Expansion of Transforming Systems’
SHREWD products at East of England region of the National Health
Service.
- Subsequent to the quarter the
Company acquired all of the issued and outstanding shares of Alamac
Limited (“Alamac”). Alamac is a UK-based company and provides
technological and advisory solutions that assist healthcare
organizations across the NHS.
Q2 2021 and 2020 Results
|
|
|
|
Three months ended |
Six months ended |
|
June 30, 2021 |
% Revenue |
June 30, 2020 |
% Revenue |
Change |
June 30, 2021 |
% Revenue |
June 30, 2020 |
% Revenue |
Change |
|
$ |
|
$ |
|
% |
$ |
|
$ |
|
% |
Revenue |
5,792,182 |
100% |
2,748,895 |
100% |
111% |
11,115,255 |
100% |
5,518,895 |
100% |
101% |
|
|
|
|
|
|
|
|
|
|
|
Cost of sales |
1,321,428 |
23% |
741,550 |
27% |
(78%) |
2,599,527 |
23% |
1,646,357 |
30% |
(58%) |
|
|
|
|
|
|
|
|
|
|
|
Gross Profit |
4,470,754 |
77% |
2,007,345 |
73% |
123% |
8,515,728 |
77% |
3,872,538 |
70% |
120% |
|
|
|
|
|
|
|
|
|
|
|
Operating Expenses |
|
|
|
|
|
|
|
|
|
|
General and administrative |
1,077,532 |
19% |
636,188 |
23% |
69% |
2,276,451 |
20% |
1,339,470 |
24% |
70% |
Sales and marketing |
917,407 |
16% |
189,296 |
7% |
385% |
1,672,037 |
15% |
462,791 |
8% |
261% |
Research and development |
1,294,271 |
22% |
425,497 |
15% |
204% |
2,452,444 |
22% |
1,133,056 |
21% |
116% |
Depreciation |
41,342 |
1% |
26,675 |
1% |
55% |
74,689 |
1% |
53,363 |
1% |
40% |
Depreciation of right-of-use assets |
67,193 |
1% |
53,386 |
2% |
26% |
130,764 |
1% |
106,846 |
2% |
22% |
Stock based compensation |
284,303 |
5% |
41,702 |
2% |
582% |
604,080 |
5% |
87,773 |
2% |
588% |
Foreign currency loss (gain) |
127,858 |
2% |
2,102 |
0% |
5982% |
192,780 |
2% |
(99,329) |
(2%) |
(294%) |
|
|
|
|
|
|
|
|
|
|
|
Other Income and Expenses |
|
|
|
|
|
|
|
|
|
|
Amortization of intangible assets |
546,845 |
9% |
443,238 |
16% |
23% |
980,816 |
9% |
886,475 |
16% |
11% |
Business acquisition, restructuring and integration costs |
612,269 |
11% |
6,659 |
0% |
9095% |
859,086 |
8% |
255,567 |
5% |
236% |
Interest expense and accretion (net of interest income) |
(7,707) |
(0%) |
(16,268) |
(1%) |
(53%) |
(18,294) |
(0%) |
7,970 |
0% |
(330%) |
Interest expense from lease liabilities |
22,770 |
0% |
19,403 |
1% |
17% |
43,381 |
0% |
40,281 |
1% |
8% |
Loss on disposal of
property and equipment |
0 |
0% |
0 |
0% |
0% |
2,497 |
0% |
0 |
0% |
100% |
|
|
|
|
|
|
|
|
|
|
|
Current income taxes |
10,071 |
0% |
0 |
0% |
100% |
10,071 |
0% |
(16,734) |
(0%) |
(160%) |
|
|
|
|
|
|
|
|
|
|
|
Net (loss) income |
(523,400) |
(9%) |
179,467 |
7% |
(392%) |
(765,074) |
(7%) |
(384,991) |
(7%) |
99% |
|
|
|
|
|
|
|
|
|
|
|
EBITDA (Non-IFRS measure) |
157,114 |
3% |
705,901 |
26% |
(78%) |
456,354 |
4% |
693,210 |
13% |
(34%) |
|
|
|
|
|
|
|
|
|
|
|
Adjusted EBITDA (Non-IFRS
measure) |
1,053,686 |
18% |
754,262 |
27% |
40% |
1,919,519 |
17% |
1,036,550 |
19% |
85% |
|
|
|
|
|
|
|
|
|
|
|
Annualized Recurring Revenue (Non-IFRS
measure) |
19,757,306 |
|
7,491,841 |
|
164% |
19,757,306 |
|
7,491,841 |
|
164% |
|
|
|
|
|
|
|
|
|
|
|
Recurring revenue (Non-IFRS
Measure) |
4,628,927 |
80% |
1,848,889 |
67% |
150% |
8,497,284 |
76% |
3,645,783 |
66% |
133% |
|
|
|
|
|
|
|
|
|
|
|
In addition, VitalHub is pleased to announce
that it has entered into a debt settlement arrangement with various
individuals in settlement of debts owed of $268,994.25 in
connection with the earn out provision as part of the Acquisition
of Transforming Systems Ltd. (the “Acquisition”). Further details
of the Acquisition are available in the Company’s August 31, 2020,
press release. Under the terms, the Company will issue 88,888
common shares of the Company at a price of $3.026 per share
ABOUT VITALHUB:
Software for Health and Human Services providers
designed to simplify the user experience & optimize
outcomes.
VitalHub provides technology to Health and Human
Services providers including; Hospitals, Regional Health
Authorities, Mental Health, Long Term Care, Home Health, Community
and Social Services. VitalHub solutions span the categories of
Electronic Health Record (EHR), Case Management, Care Coordination,
Patient Flow & Operational Visibility, and DOCit Mobile
Apps.
The Company has a robust two-pronged growth
strategy, targeting organic growth opportunities within its product
suite, and pursuing an aggressive M&A plan. Currently, VitalHub
serves 275+ clients across Canada, USA, UK, Australia, Qatar, and
Latvia. VitalHub is based in Toronto, Canada, with an offshore
development hub in Sri Lanka. The Company is publicly traded on the
TSX Venture Exchange under the symbol “VHI”.
CAUTIONARY STATEMENT:
This press release includes forward-looking
statements regarding the Corporation and its business, which may
include, but is not limited to, statements with respect to the
appointment of a new directors. Often, but not always,
forward-looking statements can be identified by the use of words
such as "plans", "is expected", "expects", "scheduled", "intends",
"contemplates", "anticipates", "believes", "proposes" or variations
(including negative variations) of such words and phrases, or state
that certain actions, events or results "may", "could", "would",
"might" or "will" be taken, occur or be achieved. Such statements
are based on the current expectations of the management of each
entity and are based on assumptions and subject to risks and
uncertainties. Although the management of each entity believes that
the assumptions underlying these statements are reasonable, they
may prove to be incorrect. The forward-looking events and
circumstances discussed in this release, may not occur by certain
specified dates or at all and could differ materially as a result
of known and unknown risk factors and uncertainties affecting the
companies, including risks regarding the technology industry,
failure to obtain regulatory or shareholder approvals, market
conditions, economic factors, the equity markets generally and
risks associated with growth and competition. Although the
Corporation has attempted to identify important factors that could
cause actual actions, events or results to differ materially from
those described in forward-looking statements, there may be other
factors that cause actions, events or results to differ from those
anticipated, estimated or intended. No forward-looking statement
can be guaranteed. Except as required by applicable securities
laws, forward-looking statements speak only as of the date on which
they are made and the Corporation undertakes no obligation to
publicly update or revise any forward-looking statement, whether as
a result of new information, future events, or otherwise.
CONTACT INFORMATION
Dan MatlowChief Executive Officer, Director(416)
727-9061dan.matlow@vitalhub.com
Vitalhub (TSXV:VHI)
Historical Stock Chart
From Nov 2024 to Dec 2024
Vitalhub (TSXV:VHI)
Historical Stock Chart
From Dec 2023 to Dec 2024